Latest News About Sens

Here’s the latest on SENS (Senseonics) based on recent public reporting.

• Recent financials and regulatory progress: Senseonics reported its Q4 and full-year 2025 results, with revenue around $14.2–14.3 million in Q4 and roughly $35 million for the full year, marking the strongest quarterly and annual performance in the company’s history. The company also announced CE Mark approval for the Eversense 365, enabling EU commercialization and planned launches in multiple European countries. This milestone positions Eversense 365 as the first one-year implantable CGM and supports future integration with automated insulin delivery systems. [Source summaries indicate these points across multiple outlets in early 2026.]

• EU expansion and product adoption: The EU CE Mark for Eversense 365 is expected to widen the company’s addressable patient population by tens of millions and pave the way for broader commercial efforts in Germany, Italy, Spain, and Sweden, among others. The EU clearance complements prior US FDA clearance and launch activity for the device. [European clearance and planned launches are reported by multiple outlets in 2026.]

• Partnerships and integration: Senseonics has been pursuing collaborations, including an integration with automated insulin delivery systems (AID), using the Eversense 365 CGM with Sequel MedTech’s twiist platform, with initial commercial patients reported and broader availability expected in 2026. These collaborations aim to expand practical use and accessibility of the 365-day CGM in conjunction with AID. [Reported in 2025–early 2026 coverage.]

If you’d like, I can pull the latest direct sources and summarize them with precise dates and figures, or focus on a specific subtopic (e.g., quarterly revenue trends, EU launch timelines, or details of the Eversense 365 regulatory status).